November 15th, 2014 – Dr. Christopher John Ong, B.Sc, Ph.D., is a Senior Research Scientist at the Vancouver Prostate Centre and an Associate Professor at the Department of Surgery and Department of Urologic Sciences, University of British Columbia has officially joined our Scientific Advisory Board. The primary focus of Dr. Ong’s research program is to understand the molecular mechanisms that govern the progression of prostate cancer from a state of androgen sensitivity to hormone independence with the hope of developing novel therapeutic strategies to prevent or delay the progression of prostate cancer to androgen independence. Dr. Ong is a scientific founder of Aquinox Pharmaceuticals Inc., a biopharmaceutical company focused on development of targeted small molecule therapeutics for treatment of cancer and inflammation. Aquinox was formed as a spin-off company from UBC, The Prostate Centre and the British Columbia Cancer Research Centre as a vehicle to facilitate the commercialization of SHIP agonists for treatment of inflammatory diseases and cancer. Aquinox has recently successfully completed an Initial Public Offering (IPO) in March, 2014 and is now publicly listed on the NASDAQ Exchange.